11:14 AM EST, 02/25/2025 (MT Newswires) -- AIM ImmunoTech ( AIM ) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's ( AZN ) Imfinzi as a potential combination to treat late-stage pancreatic cancer.

Phase 2 will also include various subjects who received the highest dose, AIM said.

The company said that up to 25 patients are expected to be enrolled in the study's phase 2.

AIM shares were down over 8% in recent trading.

Price: 0.12, Change: -0.01, Percent Change: -8.44